Skip to main content
. 2018 Sep 5;131(17):2017–2024. doi: 10.4103/0366-6999.239306

Figure 1.

Figure 1

Impact of bleeding risk on NACE among patients receiving ticagrelor versus clopidogrel. (a and b) Time-to-event curves for the NACE through 1-year follow-up in patients with low (a) or moderate-to-high bleeding risk (b); (c) Subgroup analysis on the net efficacy of ticagrelor versus clopidogrel in patients with different bleeding risk. NACE: Net adverse clinical event.